rituximab

Real-life use of the PEXIVAS reduced-dose glucocorticoid regimen in granulomatosis with polyangiitis and microscopic polyangiitis
Sophie Nagle, Yann Nguyen, Mary-Jane Guerry, Thomas Quemeneur, Dimitri Titeca-Beauport, Thomas Crépin, Rafik Mesbah, Idris Boudhabhay, Grégory Pugnet, Céline Lebas, Antoine Néel, Alexandre Karras, Eric Hachulla, Juliette Woessner, Vincent Pestre, Raphaël Borie, Stephane Vinzio, Jean-Baptiste Gouin, Sara Melboucy-Belkhir, Roderau Outh, Benjamin Subran, Mathieu Gerfaud-Valentin, Sebastien Humbert, Philippe Kerschen, Yurdagul Uzunhan, Tiphaine Goulenok, Maxime Beydon, Nathalie Costedoat-Chalumeau, Xavier Puechal, Benjamin Terrier

Annals of the Rheumatic Diseases Nov 2024, ard-2024-226339; DOI: 10.1136/ard-2024-226339
Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study
Cynthia Aranow, Cornelia F Allaart, Zahir Amoura, Ian N Bruce, Patricia C Cagnoli, Walter W Chatham, Kenneth L Clark, Richard Furie, James Groark, Murray B Urowitz, Ronald van Vollenhoven, Mark Daniels, Norma Lynn Fox, Yun Irene Gregan, Robert B Henderson, André van Maurik, Josephine C Ocran-Appiah, Mary Oldham, David A Roth, Don Shanahan, Paul P Tak, Yk Onno Teng

Annals of the Rheumatic Diseases Nov 2024, 83 (11) 1502-1512; DOI: 10.1136/ard-2024-225686
Defects in B-lymphopoiesis and B-cell maturation underlie prolonged B-cell depletion in ANCA-associated vasculitis
Jens Thiel, Franziska M Schmidt, Raquel Lorenzetti, Arianna Troilo, Iga Janowska, Lena Nießen, Sophie Pfeiffer, Julian Staniek, Bruno Benassini, Marei-Theresa Bott, Jakov Korzhenevich, Lukas Konstantinidis, Frank Burgbacher, Ann-Katrin Dufner, Natalie Frede, Reinhard E Voll, Jan Stuchly, Marina Bakardjieva, Tomas Kalina, Cristian Roberto Smulski, Nils Venhoff, Marta Rizzi

Annals of the Rheumatic Diseases Nov 2024, 83 (11) 1536-1548; DOI: 10.1136/ard-2024-225587
CD19-CAR T-cell therapy induces deep tissue depletion of B cells
Carlo Tur, Markus Eckstein, Joachim Velden, Simon Rauber, Christina Bergmann, Janina Auth, Laura Bucci, Giulia Corte, Melanie Hagen, Andreas Wirsching, Ricardo Grieshaber-Bouyer, Petra Reis, Nicolai Kittan, Jochen Wacker, Aleix Rius Rigau, Andreas Ramming, Maria-Antonietta D’Agostino, Arndt Hartmann, Fabian Müller, Andreas Mackensen, Aline Bozec, Georg Schett, Maria Gabriella Raimondo

Annals of the Rheumatic Diseases Aug 2024, ard-2024-226142; DOI: 10.1136/ard-2024-226142
More than meets the eye
Elise Siegert, Werner Stenzel, David Sinan Koca, Gerhard Krönke, Robert Biesen

Annals of the Rheumatic Diseases Aug 2024, ard-2024-226168; DOI: 10.1136/ard-2024-226168
Immunomodulators and risk for breakthrough COVID-19 after third SARS-CoV-2 mRNA vaccine among patients with rheumatoid arthritis: a cohort study
Abigail E Schiff, Xiaosong Wang, Naomi J Patel, Yumeko Kawano, Jennifer L Hanberg, Emily N Kowalski, Claire E Cook, Kathleen MM Vanni, Grace Qian, Katarina J Bade, Alene A Saavedra, Shruthi Srivatsan, Zachary K Williams, Rathnam K Venkat, Zachary S Wallace, Jeffrey A Sparks

Annals of the Rheumatic Diseases May 2024, 83 (5) 680-682; DOI: 10.1136/ard-2023-225162
Maintenance of remission of ANCA vasculitis by rituximab based on B cell repopulation versus serological flare: a randomised trial
Reza Zonozi, Frank B Cortazar, Anushya Jeyabalan, Gabriel Sauvage, Pravarut Nithagon, Noah R Huizenga, Jillian M Rosenthal, Alexander Sipilief, Katherine Cosgrove, Karen A Laliberte, Eugene P Rhee, William F Pendergraft,, John L Niles

Annals of the Rheumatic Diseases Mar 2024, 83 (3) 351-359; DOI: 10.1136/ard-2023-224489
Obinutuzumab in patients with Sjogren’s disease immunised against rituximab
Mathilde Pezot, Gaétane Nocturne, Rakiba Belkhir, Julien Henry, Stephan Pavy, Raphaèle Seror, Xavier Mariette, Samuel Bitoun

Annals of the Rheumatic Diseases Mar 2024, 83 (3) 407-408; DOI: 10.1136/ard-2023-224999
Reduced-dose versus high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: predefined 2-year follow-up study
Shunsuke Furuta, Daiki Nakagomi, Yoshihisa Kobayashi, Masaki Hiraguri, Takao Sugiyama, Koichi Amano, Takeshi Umibe, Hajime Kono, Kazuhiro Kurasawa, Yasuhiko Kita, Ryutaro Matsumura, Yuko Kaneko, Keita Ninagawa, Keiju Hiromura, Shin-ichiro Kagami, Yosuke Inaba, Hideki Hanaoka, Kei Ikeda, Hiroshi Nakajima

Annals of the Rheumatic Diseases Jan 2024, 83 (1) 96-102; DOI: 10.1136/ard-2023-224343
Short-term effectiveness and safety of rituximab versus cyclophosphamide for life-threatening ANCA-associated vasculitis: a propensity score analysis of the real-world nationwide database
Yuichi Ishikawa, Kei Tokutsu, Shingo Nakayamada, Aya Kuchiba, Kiyohide Fushimi, Shinya Matsuda, Yoshiya Tanaka

Annals of the Rheumatic Diseases Jan 2024, 83 (1) 103-111; DOI: 10.1136/ard-2023-224472

Main menu

rituximab

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

rituximab

Pages